Ajanta Pharma reported Q4 FY26 revenue of ₹1,422 crore (up 21%) and net profit of ₹267 crore (up 18%). Get clear insights into the drivers, full year performance and what it signals for Indian pharma, investors and patients.
Three former employees of a Hyderabad based pharmaceutical company were arrested on charges of allegedly extorting nearly ₹1 crore through forged documents and threats to business partners. This case sheds light on insider risks in India’s pharma sector and offers practical lessons for companies and employees alike.
Read MoreHaridwar pharma employee lost ₹1.45 crore after clicking a Facebook share market ad that led to a fake app and WhatsApp group. Here’s exactly how the scam unfolded, why it worked and the practical steps every professional can take right now to stay safe
Read MoreMedical representative in Uttar Pradesh was recently arrested in connection with the tragic deaths of his twin daughters. This case highlights the extreme pressures faced by pharma sales professionals in India and the urgent need for better mental health support. Read on for practical insights, warning signs, industry tips and real resources to help prevent similar situations.
Read MoreSun Pharma is preparing to approach the Reserve Bank of India for an exemption under foreign remittance regulations as it moves forward with the Organon acquisition. This article explains the regulatory step, why it matters and what it could mean for investors, the pharma sector and cross border deals in India.
Read MoreIn a significant ruling that could reshape how pharmaceutical companies protect their brand names, Bombay High Court has stepped in to support Sun Pharmaceutical Industries Ltd. in a high stakes trademark dispute, case revolves around two similar sounding drug brands: RACIRAFT (owned by Sun Pharma) and ESIRAFT (used by Ahmedabad based Meghmani Lifesciences Ltd.).
Read MoreIn the fast paced world of Indian pharmaceuticals, strong leadership are not just nice to have they are essential for long term success. On April 9, 2026 Gland Pharma Limited made a strategic announcement that reinforces exactly that: re appointment of Naina Lal Kidwai, a trailblazing banker and seasoned board leader, as Independent Director for a second consececutive five year term.
Read MoreIn a shocking development that has sent ripples across India’s pharmaceutical landscape, Rajasthan’s drug control authorities have issued a statewide alert over a popular antibiotic. Laboratory tests revealed that a widely distributed batch of Qcepod 200 (Cefpodoxime Proxetil 200 mg tablets) contained no active ingredient at all.
Read MoreIn the fast paced world of Indian pharmaceuticals, leadership changes can signal big shifts in strategy and growth. Today, Cipla Limited one of India’s most respected drugmakers officially entered a new chapter. Following a Board meeting on March 30, 2026 company announced that long time Managing Director and Global CEO Umang Vohra has stepped down effective April 1, 2026.
Read MoreA third year B.Pharma student named Ch. Suvarshini lost her life after jumping from the hostel building at SIR CR Reddy College of Pharmaceutical Science. This incident occurred shortly after a farewell party where she was allegedly forced to dance and teased by friends. She spoke to her family before the fall and she was immediately rushed to hospital but could not be saved.
Read MoreOn March 21,2026 company disclosed that it received a draft tax assessment order proposing additions of ₹570.51 crore to its income for FY 2022–23.
Read MoreJB Pharma has been hit with a ₹80.81 lakh GST penalty, raising questions about tax compliance in the pharma industry. What led to this action, and should investors be concerned? Here’s a complete breakdown of the case and its implications.
Read More
